Vertex Pharmaceuticals (VRTX) Other Non-Current Assets (2009 - 2026)

Vertex Pharmaceuticals' Other Non-Current Assets history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 24.73% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 24.73% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 23.75% from the prior year.
• Other Non-Current Assets climbed to $1.3 billion in Q1 2026 per VRTX's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $1.3 billion in Q1 2026 and bottomed at $110.7 million in Q1 2022.
• The 5-year median for Other Non-Current Assets is $895.3 million (2023), against an average of $734.0 million.
• Across the five-year window, Other Non-Current Assets surged 286.18% in 2023 and increased 10.89% in 2025, its largest moves.
• Year by year, Other Non-Current Assets stood at $409.6 million in 2022, then surged by 118.58% to $895.3 million in 2023, then grew by 11.62% to $999.3 million in 2024, then rose by 23.75% to $1.2 billion in 2025, then grew by 1.6% to $1.3 billion in 2026.
• Per Business Quant, the three latest VRTX Other Non-Current Assets figures stand at $1.3 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.1 billion (Q3 2025).